Trials / Completed
CompletedNCT00898911
Blood Sample Analysis in Predicting Overall Survival in Patients With Recurrent or Metastatic Head and Neck Cancer
Prediction of Overall Survival Using Mass Spectrometry Profiling in Head and Neck Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitors
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (actual)
- Sponsor
- ECOG-ACRIN Cancer Research Group · Network
- Sex
- All
- Age
- 18 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at blood sample analysis in predicting overall survival in patients with recurrent or metastatic head and neck cancer.
Detailed description
OBJECTIVES: * To validate the mass spectrometry profile that is predictive of survival benefit in patients with recurrent or metastatic head and neck squamous cell carcinoma treated with EGFR inhibitors. OUTLINE: Plasma and serum samples are analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and classified according to prognosis ("good" vs "poor") using a previously developed predictive algorithm.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | matrix-assisted laser desorption/ionization time of flight mass spectrometry |
Timeline
- Start date
- 2008-07-08
- Primary completion
- 2012-04-08
- Completion
- 2012-04-08
- First posted
- 2009-05-12
- Last updated
- 2017-05-17
Source: ClinicalTrials.gov record NCT00898911. Inclusion in this directory is not an endorsement.